821 



Mr. Waxman. And by the way, I do support uniform regulations 

 so that we don't have one jurisdiction with one law and another ju- 

 risdiction with another or one business that tries to do something 

 voluntarily, being placed at a competitive disadvantage. That's why 

 I introduced H.R. 3434. That bill would say that smokers have the 

 right to smoke in separately ventilated areas. 



I would like to ask each of you to look at that legislation. If you 

 really are sincere in your statement that you want to give smokers 

 a choice to continue to smoke, you certainly ought to give those 

 who don't want to smoke the choice not to have to breathe in some- 

 one else's tobacco smoke. I would add that this is especially impor- 

 tant in light of the information from the Surgeons General back to 

 the Nixon administration as well as the present Surgeon Greneral 

 and the Administrator of the Environmental Protection Agency, 

 that ETS is not just a nuisance, but a threat to health. 



Mr. Campbell, earlier you admitted that Dr. DeNoble's work was 

 part of developing analogues that were reenforcing, but did not 

 have peripheral effects. What was the point of this work, do you 

 know? 



Mr. Campbell. I've tried to study up on it in general terms, but 

 my colleague, Dr. Ellis, can be more specific, if you don't mind. Is 

 that all right? 



Mr. Waxman. Sure. Let's hear from her. 



Ms. Ellis. As you've already indicated, it's very important for a 

 consumer products company to understand its product. The work 

 that we have undertaken is — ^the goal of it was to do just that. The 

 goal of the comparative psychology program and the nicotine ana- 

 log program was to understand the cigarette and the product and 

 to be able to deal with the issues and the opportunities that we 

 might get from that. The program actually started in 1965. 



Mr. Waxman. Why would you look at those analogues? Were you 

 tr3dng to develop a compound that would mimic or take the place 

 of and act as a substitute for nicotine? 



Ms. Ellis. We were looking at nicotine biochemistry, nicotine ef- 

 fects, and nicotine effects in a number of different industries. Our 

 first interaction was with pharmaceutical companies and they did 

 a lot of screening for us on all effects of these analogues, including 

 agricultural uses. 



Mr. Waxman. Were you trying to see if the analogues were 

 reenforcing? 



Ms. Ellis. We were trying to look at the CNS effects of some of 

 the analogues, yes. 



Mr. Waxman. CNS means? 



Ms. Ellis. Central nervous system. 



Mr. Waxman. Were you trying to find a nicotine substitute that 

 wouldn't adversely affect the heart or any other part of the body? 



Ms. Ellis. If there were some in that category, definitely. 



Mr. Waxman. Thank you very much. Mr. Johnston, let me ask 

 you about RJR's process for nicotine control. Specifically, do you 

 monitor the nicotine levels in the tobacco leaves you use to make 

 cigarettes? 



Mr. James Johnston. Yes, we do. 



Mr. Waxman. Speak into the mike. The answer is? 



Mr. James Johnston. Yes, Mr. Chairman, we do. 



